Parkinson's disease treatment with gene-targeting therapy

Gene-targeting therapy is a cutting-edge treatment approach that uses genetic engineering to target specific genes or proteins involved in a disease. For example, in the case of Parkinson's disease, gene-targeting therapies aim to address the cause of the condition - the loss of dopamine-producing neurons. These therapies can improve motor symptoms, slow disease progression, and enhance the patient's quality of life. A suitable gene-targeting therapy is chosen based on the patient's needs and disease progression. Options include GAD (increasing GABA), AADC (boosting dopamine production), GDNF (protecting brain cells), and TH-GCH-AADC (triple gene therapy for balancing brain chemicals and enhancing dopamine production). Depending on the type, the selected gene therapy is prepared and administered through a surgical procedure or injection. This process involves introducing the therapeutic genes into the patient's brain cells, where they work to address the targeted issue. After the treatment, patients are closely monitored to assess their response to the therapy and identify potential side effects. It may involve regular medical check-ups, neurological assessments, and imaging studies. Gene-targeting therapy for Parkinson's may be used as a standalone treatment or combined with existing therapies like medications and deep brain stimulation (DBS). In addition, gene treatment can be tailored to patients' needs, enhancing treatment effectiveness.